Cargando…

Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study

INTRODUCTION: A common treatment for localized prostate cancer (PCa) is radiotherapy; however, effectiveness is hampered because of toxicities and tumor resistance. Cyclooxygenase-2 (COX-2) inhibitors have been identified as potential agents that could improve treatment outcomes and have demonstrate...

Descripción completa

Detalles Bibliográficos
Autores principales:	King, Liam, Christie, David, Arora, Devinder, Anoopkumar-Dukie, Shailendra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Pacific Prostate Society 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125379/ https://www.ncbi.nlm.nih.gov/pubmed/32257976 http://dx.doi.org/10.1016/j.prnil.2019.10.004

Ejemplares similares

Drivers of Radioresistance in Prostate Cancer
por: King, Liam, et al.
Publicado: (2022)

A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated with radiotherapy
por: Hart, Jordan, et al.
Publicado: (2020)

Protection against Radiotherapy-Induced Toxicity
por: Hall, Susan, et al.
Publicado: (2016)

The Association between Prostate-Specific Antigen Velocity (PSAV), Value and Acceleration, and of the Free PSA/Total PSA Index or Ratio, with Prostate Conditions
por: Flores-Fraile, María-Carmen, et al.
Publicado: (2020)

The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers
por: Batty, Mallory, et al.
Publicado: (2016)

Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity
por: Stephan, Carsten, et al.
Publicado: (2008)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

SIRT1 and SIRT2 Modulators: Potential Anti-Inflammatory Treatment for Depression?
por: Zhang, Yuqing, et al.
Publicado: (2021)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Denosumab: Delay of bone metastasis in men with nonmetastatic castrate-resistant prostate cancer
por: Manger, Jules P., et al.
Publicado: (2012)

Involvement of indoleamine 2, 3-dioxygenase (IDO) and brain-derived neurotrophic factor (BDNF) in the neuroprotective mechanisms of ferulic acid against depressive-like behaviour
por: Mallik, Sanchari Basu, et al.
Publicado: (2023)

Molecular Mechanisms Underlying the Effects of Statins in the Central Nervous System
por: McFarland, Amelia J., et al.
Publicado: (2014)

A Review of Black Salve: Cancer Specificity, Cure, and Cosmesis
por: Croaker, Andrew, et al.
Publicado: (2017)

Sanguinaria canadensis: Traditional Medicine, Phytochemical Composition, Biological Activities and Current Uses
por: Croaker, Andrew, et al.
Publicado: (2016)

What is the possible role of PSA doubling time (PSADT) and PSA velocity (PSAV) in the decision-making process to initiate salvage radiotherapy following radical prostatectomy in patients with prostate cancer?
por: Milecki, Piotr, et al.
Publicado: (2011)

Putative involvement of sirtuin modulators in LPS-induced sickness behaviour in mice
por: Kinra, Manas, et al.
Publicado: (2022)

Prostate biopsy for elevated prostate specific antigen (PSA) – Indian perspective
por: Ragavan, N.
Publicado: (2014)

The SAMe-TT(2)R(2) Score Predicts Warfarin Control in an Australian Population with Atrial Fibrillation
por: Bernaitis, Nijole, et al.
Publicado: (2019)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Characteristics of PSA Bounce after Radiotherapy for Prostate Cancer: A Meta-Analysis
por: Darwis, Narisa Dewi Maulany, et al.
Publicado: (2020)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy
por: Yoshida, Soichiro, et al.
Publicado: (2021)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)
por: Stephan, Carsten, et al.
Publicado: (2014)

The Use of Fish Oil with Warfarin Does Not Significantly Affect either the International Normalised Ratio or Incidence of Adverse Events in Patients with Atrial Fibrillation and Deep Vein Thrombosis: A Retrospective Study
por: Pryce, Rebecca, et al.
Publicado: (2016)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

RADIOTHERAPY OF PROSTATE CANCER: PRIMARY RADIOTHERAPY AND RADIOTHERAPY IN DISEASE RELAPSE
por: Antunac, Katarina
Publicado: (2019)

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2022)

Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
por: Schultz, Neil M., et al.
Publicado: (2020)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer
por: Chavan, Sushant V., et al.
Publicado: (2014)

The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
por: Paller, CJ, et al.
Publicado: (2013)

Prostate-Specific Antigen (PSA) and Prostate Volume: Better Predictor of Prostate Cancer for Bosnian and Herzegovina Men
por: Coric, Jozo, et al.
Publicado: (2015)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival
por: Doherty, A P, et al.
Publicado: (2000)

Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers
por: Filella, Xavier, et al.
Publicado: (2016)

PROSTATE-SPECIFIC ANTIGEN (PSA) VALUES IN PATIENTS WITH LOW- AND HIGH-RISK PROSTATIC ADENOCARCINOMA
por: Mašić, Silvija, et al.
Publicado: (2019)

Editorial Comment to Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy
por: Hirayama, Yukiyoshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v1kdn7iljtjho0gldopa8j6gue